Patrick P. Zarrinkar
Founder at Recludix Pharma, Inc.
Profile
Patrick P.
Zarrinkar founded Recludix Pharma, Inc., where he worked as President & Chief Scientific Officer.
Dr. Zarrinkar also formerly worked at Molecular Simulations, Inc., as Chief Operating Officer, Senomyx, Inc., as Chief Operating Officer, Pharmacopeia LLC, as Chief Operating Officer, Ambit Biosciences Corp., as VP-Technology Development & Alliance Management, and Novartis Institute for Functional Genomics, Inc., as Staff Scientist.
Dr. Zarrinkar received his doctorate degree from Massachusetts Institute of Technology and undergraduate degree from the University of South Carolina.
Patrick P. Zarrinkar active positions
| Companies | Position | Start |
|---|---|---|
Recludix Pharma, Inc.
 Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | Founder | - |
Former positions of Patrick P. Zarrinkar
| Companies | Position | End |
|---|---|---|
Molecular Simulations, Inc.
 Molecular Simulations, Inc. Packaged SoftwareTechnology Services Molecular Simulations, Inc. is a provider of predictive modeling software. The company is based in San Diego, CA and has subsidiaries in the United States. The company was founded by Stephen L. Mayo. Molecular Simulations was acquired by BIOVIA, Inc., part of Dassault Systèmes SA from April 30, 2014 on June 12, 1998 for $119.85 million. | Chief Operating Officer | - |
Pharmacopeia LLC
 Pharmacopeia LLC Pharmaceuticals: MajorHealth Technology Pharmacopeia LLC develops small molecule therapeutics to address significant medical needs. The firm operates as clinical development stage Biopharmaceutical Company which focuses on discovering and developing novel small molecule therapeutics to address medical needs. The company was founded by John J. Baldwin in February 2002 and is headquartered in Cranbury, NJ. | Chief Operating Officer | - |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | - |
| SENOMYX INC. | Chief Operating Officer | - |
| AMBIT BIOSCIENCES CORP | Chief Tech/Sci/R&D Officer | - |
Training of Patrick P. Zarrinkar
| University of South Carolina | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Ambit Biosciences Corp.
 Ambit Biosciences Corp. Pharmaceuticals: MajorHealth Technology Ambit Biosciences Corp. develops pharmaceutical drugs. It engages in discovery, development and commercialization of small-molecule kinase inhibitors for the treatment of cancer. The firm provides drug to treat unmet medical needs in oncology, autoimmune and inflammatory diseases. The company was founded on May 17, 2000 and is headquartered in San Diego, CA. | Health Technology |
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Commercial Services |
Senomyx, Inc.
 Senomyx, Inc. Food: Specialty/CandyConsumer Non-Durables Senomyx, Inc. engages in the development and commercialization of flavor ingredients for the packaged food, beverage, and ingredient supply industries. It develops high intensity sweeteners, savory flavors, bitter taste blockers, and cooling agents. The company was founded by Paul A. Grayson, Lubert Stryer, Yon Chien Tsien, Denis Baylor, Harold McGee, and Charles Zuker on September 16, 1998 and is headquartered in San Diego, CA. | Consumer Non-Durables |
Pharmacopeia LLC
Pharmacopeia LLC Pharmaceuticals: MajorHealth Technology Pharmacopeia LLC develops small molecule therapeutics to address significant medical needs. The firm operates as clinical development stage Biopharmaceutical Company which focuses on discovering and developing novel small molecule therapeutics to address medical needs. The company was founded by John J. Baldwin in February 2002 and is headquartered in Cranbury, NJ. | Health Technology |
Molecular Simulations, Inc.
Molecular Simulations, Inc. Packaged SoftwareTechnology Services Molecular Simulations, Inc. is a provider of predictive modeling software. The company is based in San Diego, CA and has subsidiaries in the United States. The company was founded by Stephen L. Mayo. Molecular Simulations was acquired by BIOVIA, Inc., part of Dassault Systèmes SA from April 30, 2014 on June 12, 1998 for $119.85 million. | Technology Services |
Recludix Pharma, Inc.
Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | Commercial Services |
- Stock Market
- Insiders
- Patrick P. Zarrinkar
